Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 13 | 2024 | 434 | 2.920 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2024 | 187 | 0.970 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 3 | 2024 | 395 | 0.850 |
Why?
|
| Consensus | 1 | 2024 | 610 | 0.740 |
Why?
|
| Lung | 3 | 2024 | 1466 | 0.590 |
Why?
|
| Actigraphy | 2 | 2024 | 44 | 0.450 |
Why?
|
| Hemodynamics | 3 | 2022 | 844 | 0.320 |
Why?
|
| Infant, Newborn | 8 | 2024 | 8118 | 0.280 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 439 | 0.270 |
Why?
|
| Infant | 9 | 2024 | 12379 | 0.260 |
Why?
|
| SOXF Transcription Factors | 1 | 2024 | 18 | 0.240 |
Why?
|
| Registries | 1 | 2020 | 1397 | 0.220 |
Why?
|
| Child, Preschool | 8 | 2024 | 13916 | 0.210 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2024 | 145 | 0.200 |
Why?
|
| Heart Rate | 1 | 2024 | 587 | 0.190 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 458 | 0.190 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 204 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2024 | 378 | 0.180 |
Why?
|
| Biopsy | 1 | 2024 | 1236 | 0.180 |
Why?
|
| Patient Care Team | 1 | 2024 | 549 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2022 | 190 | 0.170 |
Why?
|
| Sildenafil Citrate | 2 | 2016 | 51 | 0.160 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 140 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 2021 | 164 | 0.160 |
Why?
|
| Infant, Premature | 2 | 2023 | 804 | 0.160 |
Why?
|
| Length of Stay | 1 | 2024 | 1289 | 0.160 |
Why?
|
| Humans | 20 | 2024 | 123305 | 0.160 |
Why?
|
| Echocardiography | 2 | 2021 | 1049 | 0.150 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2007 | 2 | 0.150 |
Why?
|
| Mitochondrial Diseases | 1 | 2020 | 135 | 0.150 |
Why?
|
| Child | 10 | 2024 | 24264 | 0.150 |
Why?
|
| Hemophilia A | 1 | 2007 | 20 | 0.140 |
Why?
|
| Collateral Circulation | 1 | 2017 | 45 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 360 | 0.140 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2017 | 42 | 0.140 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2017 | 19 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 80 | 0.140 |
Why?
|
| Paclitaxel | 1 | 2017 | 120 | 0.140 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2017 | 64 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 335 | 0.140 |
Why?
|
| Prognosis | 3 | 2021 | 4515 | 0.140 |
Why?
|
| Premature Birth | 1 | 2021 | 382 | 0.130 |
Why?
|
| Growth Differentiation Factors | 1 | 2016 | 11 | 0.130 |
Why?
|
| Angioplasty, Balloon | 1 | 2017 | 161 | 0.130 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 702 | 0.120 |
Why?
|
| Disease Progression | 1 | 2021 | 2031 | 0.120 |
Why?
|
| Hypotension | 1 | 2016 | 177 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2020 | 1020 | 0.120 |
Why?
|
| Mexican Americans | 1 | 2016 | 204 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2024 | 6032 | 0.120 |
Why?
|
| Pandemics | 1 | 2021 | 1101 | 0.110 |
Why?
|
| Female | 11 | 2024 | 65618 | 0.110 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 631 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 224 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 216 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 250 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16066 | 0.100 |
Why?
|
| Walk Test | 2 | 2024 | 24 | 0.100 |
Why?
|
| Adolescent | 6 | 2024 | 19132 | 0.090 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 448 | 0.090 |
Why?
|
| Male | 11 | 2024 | 60282 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3547 | 0.080 |
Why?
|
| Mutation | 2 | 2020 | 5768 | 0.080 |
Why?
|
| Pregnancy | 1 | 2021 | 7156 | 0.070 |
Why?
|
| Exercise | 2 | 2024 | 816 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5050 | 0.060 |
Why?
|
| Survival Rate | 1 | 2020 | 2001 | 0.060 |
Why?
|
| Sample Size | 1 | 2024 | 85 | 0.060 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 19 | 0.050 |
Why?
|
| Age Factors | 1 | 2020 | 2805 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 50 | 0.050 |
Why?
|
| Anticoagulants | 2 | 2017 | 581 | 0.050 |
Why?
|
| Syndrome | 1 | 2024 | 1116 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 756 | 0.050 |
Why?
|
| Time Factors | 2 | 2024 | 6228 | 0.050 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 27 | 0.040 |
Why?
|
| Dilatation | 1 | 2020 | 68 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 1801 | 0.040 |
Why?
|
| Gestational Age | 1 | 2023 | 1139 | 0.040 |
Why?
|
| Heart Atria | 1 | 2020 | 313 | 0.040 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2007 | 3 | 0.040 |
Why?
|
| Ecchymosis | 1 | 2007 | 11 | 0.040 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 30 | 0.040 |
Why?
|
| Heart | 1 | 2022 | 723 | 0.040 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 55 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 195 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 91 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 101 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 152 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 32 | 0.030 |
Why?
|
| Polysomnography | 1 | 2017 | 142 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 2852 | 0.030 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 8871 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 143 | 0.030 |
Why?
|
| Epoprostenol | 1 | 2016 | 67 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 131 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 421 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 537 | 0.030 |
Why?
|
| United States | 1 | 2020 | 10667 | 0.030 |
Why?
|
| Warfarin | 1 | 2016 | 118 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 725 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 69 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 89 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2007 | 458 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 669 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 532 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 259 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 29087 | 0.030 |
Why?
|
| Anemia | 1 | 2007 | 341 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2017 | 316 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 4709 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 398 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 216 | 0.030 |
Why?
|
| Aged | 1 | 2020 | 19173 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1877 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2017 | 958 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12168 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1610 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 26075 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2058 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3240 | 0.020 |
Why?
|